Silvaco Group, Inc. provides technology computer aided design (TCAD) software, electronic design automation (EDA) software, and semiconductor intellectual property (SIP) solutions in the United States and internationally. The company's TCAD software are used in semiconductor industry to model and optimize manufacturing process and device performance. Its EDA software solution include spice modelling, and simulation, parasitic extraction and reduction, standard cell generation and optical proximity correction. The company also provides SIP and EDA software and design services, such as standard cell library development; and embedded memory compilers. Further, the company provides SIP management tools and SIP. It serves semiconductor manufacturers, original equipment manufacturers, and original design manufacturers that deploys solutions in production flows across various target markets, including display, power devices, automotive, memory, high performance computing, Internet of Things, and 5G/6G mobile markets. The company has a partnership with Dassault Systèmes to develop interoperable digital twin workflows for semiconductor manufacturing. The company was founded in 1984 and is headquartered in Santa Clara, California.…
Silvaco Group (SVCO) Q3 2026 Earnings Call Transcript
Silvaco CEO Dr. Walden “Wally” Rhines Inducted into the National Academy of Engineering
Silvaco Group (NASDAQ: SVCO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Software - Application industry, part of the Technology sector, and reports about 406 employees.
The shares were at 6.660 USD on 20 November 2026, up 36.2% over 52 weeks. Its 52-week range is 3.070 USD to 14.39 USD: the price is 53.7% below the high and 116.9% above the low.
Its market capitalisation is 227.75M USD.
Silvaco Group reports return on equity of -54.9%, an operating margin of -24.1% and revenue down 12.7% year over year.
It holds more cash than debt, a net cash position of 6.95M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 6 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 14.00 USD is 110.2% above the current price. The next earnings report is expected on 11 March 2027.